Can Nitric Oxide-Releasing Hybrid Drugs Alleviate Adverse Cardiovascular Risks?

Future Medicinal ChemistryVol. 5, No. 4 OpinionCan nitric oxide-releasing hybrid drugs alleviate adverse cardiovascular risks?Atul Bhardwaj, Jatinder Kaur & Edward E KnausAtul Bhardwaj* Author for correspondenceFaculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada Department of Oncology, University of Alberta, Edmonton, AB, Canada. , Jatinder KaurFaculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada Department of Oncology, University of Alberta, Edmonton, AB, Canada & Edward E KnausFaculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB, CanadaPublished Online:15 Mar 2013https://doi.org/10.4155/fmc.13.23AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: cardiovascular riskCOXdiabetesendothelial dysfunctioninflammationnitric oxideReferences1 Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation100,1134–1146 (1999).Crossref, Medline, CAS, Google Scholar2 Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in Type 2 diabetes mellitus: insights from mechanistic studies. Lancet371,1800–1809 (2008).Crossref, Medline, CAS, Google Scholar3 Bhattacharyya OK, Shah BR, Booth GL. Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CA Med. Assoc. J.179,920–926 (2008).Crossref, Google Scholar4 Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension26,869–879 (1995).Crossref, Medline, CAS, Google Scholar5 Toda N, Imamura T, Okamura T. Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus. Pharmacol. Therap.127,189–209 (2010).Crossref, Medline, CAS, Google Scholar6 Keeble JE, Moore PK. Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol.137(3),295–310 (2002).Crossref, Medline, CAS, Google Scholar7 Butler AR, Williams DLH. The physiological role of nitric oxide. Chem. Soc. Rev.22,233–241 (1993).Crossref, CAS, Google Scholar8 Napoli C, Ignarro LJ. Nitric oxide-releasing drugs. Annu. Rev. Pharmacol. Toxicol.43,97–123 (2003).Crossref, Medline, CAS, Google Scholar9 Virsaladze D, Kipiani V. Endothelial dysfunction in diabetic vasculopathy. Ann. Biochem. Res. Educ.1,44–48 (2001).Google Scholar10 Rahman S, Rahman T, Ismail AA, Rashid AR. Diabetes associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes. Metab.9,767–780 (2007).Crossref, Medline, CAS, Google Scholar11 Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care33,1389–1394 (2010).Crossref, Medline, Google Scholar12 Cooper ME, Bonnet F, Oldfield M, Jandeleit-Dahm K. Mechanisms of diabetic vasculopathy: an overview. Am. J. Hypertens.14,475–486 (2001).Crossref, Medline, CAS, Google Scholar13 Simmons DL, Botting RM, Hla T. Cyclooxygenase Isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev.56,387–437 (2004).Crossref, Medline, CAS, Google Scholar14 Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem.50,1425–1441 (2007).Crossref, Medline, CAS, Google Scholar15 Fitzgerald GA. Coxibs and cardiovascular disease. N. Engl. J. Med.351,1709–1711 (2004).Crossref, Medline, CAS, Google Scholar16 Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest.116,4–15 (2006).Crossref, Medline, CAS, Google Scholar17 Calderone V. An update on hybrid drugs in cardiovascular drug research. Expert Opin. Drug. Discov.3(12),1397–1408 (2008).Crossref, Medline, CAS, Google Scholar18 Kaur J, Bhardwaj A, Huang Z et al. Synthesis and biological investigations of nitric oxide releasing nateglinide and meglitinide Type 2 antidiabetic prodrugs: in vivo antihyperglycemic activities and blood pressure lowering studies. J. Med. Chem.55,7883–7891 (2012).Crossref, Medline, CAS, Google Scholar19 Bhardwaj A, Huang Z, Kaur J, Knaus EE. Rofecoxib analogues possessing a nitric oxide donor sulfohydroxamic acid (SO2NHOH) cyclooxygenase-2 pharmacophore: synthesis, molecular modeling, and biological evaluation as anti-inflammatory agents. ChemMedChem7,62–67 (2012).Crossref, Medline, CAS, Google Scholar20 Bhardwaj A, Batchu SN, Kaur J, Huang Z, Seubert JM, Knaus EE. Cardiovascular properties of a nitric oxide releasing rofecoxib analog: beneficial antihypertensive activity and enhanced recovery in an ischemic reperfusion injury model. ChemMedChem7,1365–1368 (2012).Crossref, Medline, CAS, Google Scholar21 Chiroli V, Benedini F, Ongini E, Soldato PD. Nitric oxide-donating non-steroidal anti-inflammatory drugs: the case of nitroderivatives of aspirin. Eur. J. Med. Chem.38,441–446 (2003).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByTadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failureLife Sciences, Vol. 289Synthesis and Biological Evaluation of 1,3,5‐Trisubstituted 2‐Pyrazolines as Novel Cyclooxygenase‐2 Inhibitors with Antiproliferative Activity23 February 2021 | Chemistry & Biodiversity, Vol. 18, No. 3PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trialsInternational Journal of Cardiology, Vol. 172, No. 3The importance of drug discovery for treatment of cardiovascular diseasesCharles Kennedy15 March 2013 | Future Medicinal Chemistry, Vol. 5, No. 4 Vol. 5, No. 4 STAY CONNECTED Metrics Downloaded 104 times History Published online 15 March 2013 Published in print March 2013 Information© Future Science LtdKeywordscardiovascular riskCOXdiabetesendothelial dysfunctioninflammationnitric oxideAcknowledgementsA Bhardwaj and J Kaur are grateful to P Singh from Guru Nanak Dev University, Amritsar, India and S Verma form the Indian Institute of Technology, Kanpur, India, for their valuable suggestions and support. A Bhardwaj and J Kaur are also thankful to F Wuest from the Department of Oncology, University of Alberta, Canada, for postdoctoral Fellowship and guidance.Financial & competing interests disclosureThe authors are grateful to the Canadian Institutes of Health Research (grant no. MOP-14712) for financial support of this research. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.